FINANCIAL PROCEDURE FOR SUPPORTING NON-COMMERCIAL RESEARCH - Version 2 - financial procedure

Sep 11, 2026

Upload by Aria

Financial Procedure for Supporting Non-Commercial Research sets out how Cardiff and Vale UHB costs non-commercially sponsored research proposals using information provided through the Integrated Research Application System (IRAS) form, study protocol, and supporting documentation. It applies to the C&V UHB R&D Office and Finance Department, ensuring costs are appropriately allocated and that research-related income is managed with accountability and transparency, without routinely drawing on clinical service or patient care budgets.

LanguageEnglish

CategoryLetters

FormatPDF

Pages13

Reading Time5 min

AccessFree to download

Introduction and Aim

Objectives

Scope

Equality Health Impact Assessment

Documents to read alongside this Procedure

Roles and Approvals

Summary of reviews/amendments

Procedure Overview

Funding model and budget ring-fencing

Costing of research proposals

Disclaimer If the review date of this document has passed please ensure that the version you are using is the most up to date either by contacting the document author or the Governance Directorate. | Reference Number: UHB 487
Version Number: 2 | | Date of Next Review: 02.11.2026
Previous Trust/LHB Reference Number:
N/A | | --- | --- | --- | | FINANCIAL PROCEDURE FOR SUPPORTING NON-COMMERCIAL RESEARCH | | | | Introduction and Aim
To describe the procedure for costing non-commercially sponsored research projects from the information provided by the Principal/Chief Investigator on the Integrated Research Application System Form (IRAS), study protocol and other relevant documentation. | | | | Objectives
To ensure that non-commercially sponsored research projects are costed appropriately | | | | Scope
This Standard Operating Procedure is for use by the C&V UHB R&D Office and Finance Department, for non-commercially sponsored research. It does not apply to commercially sponsored research where the entire costs are covered by the commercial company (usually a pharmaceutical company or medical device company) and are determined using the NIHR ‘Industry‘ costing template by the Commercials Trials Office of R&D in collaboration with the local research team and support departments and negotiated with the commercial company.
Before confirming Capacity and Capability for an R & D study, the resource implications of delivering research within an NHS care setting must be accurate and clear. This procedure outlines the process for the production of financial information to support study applications but does not consider the process for final study approval. | | | | Equality Health Impact Assessment | An Equality Health Impact Assessment (EHIA) has not been completed because the SOP has been written to support the implementation the Research Governance and the UHB Finance Policies. The Equality Impact Assessment completed for the policy found no impact. | | | Documents to read alongside this Procedure | NHS R&D Finance Policy Template Version 01 February 2017 (Expected to be updated during 2023/24) | | | Approved by | Joint Research Governance Group | | | Accountable Executive or Clinical Board Director | Executive Director of Finance | | | Author | Finance Manager (Resource Management) | | | Summary of reviews/amendments | | | | | --- | --- | --- | --- | | Version
Number | Date of Review Approved | Date
Published | Summary of Amendments | | 1 | 20/10/2020 | 20/04/2021 | Document updated to reflect the new UHB format
Page 1: Scope of procedure clarified. Reference to CaRRs removed
Section 1, page 3-4: Minor changes in wording to provide update on: HCRW funding strategy and levels; and refer to the Welsh Government NHS R & D Funding Policy
Section 1, Page 4: Move away from SSI to UK Local Information Pack referenced.
Section 3; Revised arrangements for funding of Specialist ETC identified.
Section 4.4 Reference to Risk assessment form removed.
Section 5.2 page 7: Move away from SSI to Local information Pack including schedule of events referenced and summarised.
Section 5.3 page 7: Communication of costed schedules clarified.
Section 5.3 page 8: Government Accounting rules in respect of deferred income included.
Appendix 2 Updated to reflect revised costing template | | 2 | 02/11/2023 | 28.11.2023 | Section 1 , para 1,3 & 4: Research & Development funding amended to All Wales Research Delivery Funding.
Section 1, para 2 Historical context removed
Section 1, para 7 reference to HCRW annual report removed | | | | | Section 2 , Page 4: reference to AcoRD inserted Page 5 Revised ETC links
Section 5, Page 5 Revised ETC links
Section 5.5 , Paragraph referring to R & D annual report for HCRW removed
Appendix 1 , Key R & D Contacts has been removed due to consistent changes in staff | | --- | --- | --- | --- | | Document Title: Financial Procedure for

FAQs

What is the purpose of this financial procedure for non-commercial research?

It describes the process for costing non-commercially sponsored research projects using information from IRAS, the study protocol, and related documentation, so projects are costed appropriately.

Which teams use this procedure and what types of research does it cover?

It is for the C&V UHB R&D Office and Finance Department for non-commercially sponsored research. It does not apply to commercially sponsored research where costs are covered by the commercial company.

How does the procedure address funding governance and accountability?

It emphasizes that research-related funding and income require comprehensive accountability and transparency, ensuring income covers incurred research costs without routinely using clinical service or patient care budgets.

Sep 11, 2026

Upload by Aria